Citation & Authors
Clin Gastroenterol Hepatol. 2024;22(6):1255-1264.e18.
ABSTRACT · RESEARCH SUMMARY
Research summary
This matched cohort study using Taiwanese National Health Insurance data included 467 patient pairs. GLP-1 receptor agonist users had a lower risk of death (aHR 0.47; 95% CI 0.32–0.69), as well as fewer cardiovascular events, decompensated cirrhosis, hepatic encephalopathy, and hepatic failure. The findings apply to the studied population with type 2 diabetes and compensated cirrhosis and require further validation.
Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗
